ProPhase Labs (NASDAQ:PRPH) Shares Pass Below 200 Day Moving Average – Time to Sell?

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares traded.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a research note on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ProPhase Labs has an average rating of “Sell”.

ProPhase Labs Stock Down 8.1%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The firm has a market capitalization of $452,252.20, a price-to-earnings ratio of -0.02 and a beta of -0.52. The firm has a fifty day moving average price of $0.15 and a 200 day moving average price of $1.86.

Institutional Investors Weigh In On ProPhase Labs

Several institutional investors have recently made changes to their positions in PRPH. XTX Topco Ltd acquired a new position in shares of ProPhase Labs during the 2nd quarter worth $40,000. Apollon Wealth Management LLC purchased a new stake in ProPhase Labs during the third quarter worth about $84,000. Accretive Wealth Partners LLC purchased a new stake in ProPhase Labs during the third quarter worth about $114,000. Finally, Susquehanna International Group LLP grew its position in ProPhase Labs by 290.1% during the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after buying an additional 295,899 shares during the period. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.